Dr. Alex F. Herrera, MD

Dr. Herrera practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Dr. Herrera's NPI, 1275761553, was assigned on June 25, 2009. Dr. Herrera graduated from Harvard Medical School in 2009. Dr. Herrera holds California license A130569.

Dr. Herrera's primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (800) 826-4673.

Dr. Herrera's primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. The medical group on file is City of Hope. Dmand AI also links Dr. Herrera to 1 more other site, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Herrera practices. Vendor and product names are available with a free account.

Internal medicine is Dr. Herrera's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Herrera is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Herrera's licenses on file in 2 states: California and Massachusetts.

Dmand AI lists lymphoma and multiple myeloma among the conditions Dr. Herrera treats.

CMS data shows 420 Medicare services from Dr. Herrera across 5 procedure codes in 2024, for 129 Medicare patients. Medicare paid $34,795 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 129 Medicare patients who saw Dr. Herrera in 2024. The largest group is 65 to 74, with 59 patients. 70% of them have high cholesterol, and 61% have high blood pressure. 35% are also on Medicaid. Their average risk score is 2.99, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Herrera's median patient age at 65, with 40% women.

In 2024, Dr. Herrera wrote 82 Medicare Part D claims for 24 patients. 71% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $80 in total drug cost. In 2021, CMS named 12 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Herrera for performance year 2024, reported as part of a group. Dr. Herrera accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Herrera as offering telehealth.

Dmand AI links 133 papers to Dr. Herrera, published from 2014 to 2025. 2023 was the busiest year, with 11. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Lymphoma, Large B-Cell, Diffuse and Hematopoietic Stem Cell Transplantation. Dr. Herrera has published most often in Blood. Dr. Herrera's most frequent co-authors are Matthew Genyeh Mei, MD, Stephen J. Forman, MD and Leslie L. Popplewell, MD.

Dmand AI links Dr. Herrera to 11 clinical trials, 5 of them phase 1/2 studies. 5 are still active or recruiting. Conditions studied include Lymphoma, Hodgkin Disease and Lymphoma, Follicular. City of Hope Medical Center sponsors the most, 5.

CMS Open Payments shows 235 general payments to Dr. Herrera from 24 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 79% of the total. Bristol-Myers Squibb Company paid the most, $37,685. It also lists 30 research payments totaling $17,610 from 2020 to 2025.

Dmand AI lists 10 awards for Dr. Herrera, most recently City of Hope K12 City of Hope Clinical Oncology Career Research Development Program Recipient in 2015.

Dr. Herrera graduated from Harvard Medical School in 2009. Dr. Herrera is a member of ASCO.

Dr. Herrera is in network with 14 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 8. Check the plan with the practice before a visit.